Invention Grant
US07807642B2 Tumor-associated peptides binding promiscuosly to human leukocyte antigen (HLA) class II molecules
有权
肿瘤相关肽预先结合人白细胞抗原（HLA）II类分子
- Patent Title: Tumor-associated peptides binding promiscuosly to human leukocyte antigen (HLA) class II molecules
- Patent Title (中): 肿瘤相关肽预先结合人白细胞抗原（HLA）II类分子
-
Application No.: US11942573Application Date: 2007-11-19
-
Publication No.: US07807642B2Publication Date: 2010-10-05
- Inventor: Jörn Dengjel
- Applicant: Jörn Dengjel
- Applicant Address: DE Tubingen
- Assignee: Immatics Biotechnologies GmbH
- Current Assignee: Immatics Biotechnologies GmbH
- Current Assignee Address: DE Tubingen
- Agency: Baker, Donelson, Bearman, Caldwell & Berkowitz, PC
- Priority: EP05019254 20050905
- Main IPC: A61K38/00
- IPC: A61K38/00
Abstract:
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Public/Granted literature
- US20080207520A1 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules Public/Granted day:2008-08-28
Information query
IPC分类:
